Abstract:α2δ auxiliary subunits of voltage‐gated calcium channels modulate the calcium currents and have emerged as regulators of synaptic functions. Considering these important functions, it is not surprising that mutations of α2δ‐2 are associated with developmental and epileptic encephalopathy (DEE). However, whether an altered calcium channel modulation, synaptic mechanism, or both underlie the disease phenotype is not known. Here, we functionally characterized a homozygous missense mutation identified in two siblings with DEE. Our study strongly links the mutation to the underlying disorder and demonstrates that disruption in both channel‐dependent as well as pre‐ and postsynaptic functions of α2δ‐2 can contribute to the pathophysiological mechanism. α2δ proteins serve as auxiliary subunits of voltage‐gated calcium channels and regulate channel membrane expression and current properties. Besides their channel function, α2δ proteins regulate synapse formation, differentiation, and synaptic wiring. Considering these important functions, it is not surprising that CACNA2D1‐4, the genes encoding for α2δ‐1 to ‐4 isoforms, have been implicated in neurological, neurodevelopmental, and neuropsychiatric disorders. Mutations in CACNA2D2 have been associated with developmental and epileptic encephalopathy (DEE) and cerebellar atrophy. In our present study, we performed a detailed functional characterization of the p.R593P mutation in α2δ‐2, a homozygous mutation previously identified in two siblings with DEE. Importantly, we analyzed both calcium channel‐dependent as well as synaptic functions of α2δ‐2. Our data show that the corresponding p.R596P mutation in mouse α2δ‐2 drastically decreases membrane expression and synaptic targeting of α2δ‐2. This defect correlates with altered biophysical properties of postsynaptic CaV1.3 channel but has no effect on presynaptic CaV2.1 channels upon heterologous expression in tsA201 cells. However, homologous expression of α2δ‐2_R596P in primary cultures of hippocampal neurons affects the ability of α2δ‐2 to induce a statistically significant increase in the presynaptic abundance of endogenous CaV2.1 channels and presynaptic calcium transients. Moreover, our data demonstrate that in addition to lowering membrane expression, the p.R596P mutation reduces the trans‐synaptic recruitment of GABAA receptors and presynaptic synapsin clustering in glutamatergic synapses. Lastly, the α2δ‐2_R596P reduces the amplitudes of glutamatergic miniature postsynaptic currents in transduced hippocampal neurons. Taken together, our data strongly link the human biallelic p.R593P mutation to the underlying severe neurodevelopmental disorder and highlight the importance of studying α2δ mutations not only in the context of channelopathies but also synaptopathies.

A precision medicine approach for Developmental and Epileptic Encephalopathy

Identification of Small-Molecule Ion Channel Modulators in C. Elegans Channelopathy Models.

Functional characterization and in vitro pharmacological rescue of KCNQ2 pore mutations associated with epileptic encephalopathy

Antisense oligonucleotide therapy for KCNT1 encephalopathy

Epilepsy-linked kinase CDKL5 phosphorylates voltage-gated calcium channel Cav2.3, altering inactivation kinetics and neuronal excitability

Voltage-Gated Ion Channel Compensatory Effect in DEE: Implications for Future Therapies

Clinical analysis and functional characterization of KCNQ2-related developmental and epileptic encephalopathy

Electrophysiological Features: the Next Precise Step for SCN2A Developmental Epileptic Encephalopathy

A structurally precise mechanism links an epilepsy-associated KCNC2 potassium channel mutation to interneuron dysfunction

Variant‐specific in vitro neuronal network phenotypes and drug sensitivity in SCN2A developmental and epileptic encephalopathy

Plural molecular and cellular mechanisms of pore domain KCNQ2 encephalopathy

Targeted gene panel and genotype-phenotype correlation in children with developmental and epileptic encephalopathy

KCNA1 gain‐of‐function epileptic encephalopathy treated with 4‐aminopyridine

Investigation of novel de novo KCNC2 variants causing severe developmental and early-onset epileptic encephalopathy

The phenotype and treatment of SCN2A-related developmental and epileptic encephalopathy

Antisense oligonucleotide therapy for SCN2A gain-of-function epilepsy

Development of KCC2 therapeutics to treat neurological disorders

Allele‐Specific Editing of a Dominant SCN8A Epilepsy Variant Protects against Seizures and Lethality in a Murine Model

A biallelic mutation in CACNA2D2 associated with developmental and epileptic encephalopathy affects calcium channel‐dependent as well as synaptic functions of α2δ‐2

424 Clinical Translational Approach to Targeted Therapy in SLC6A1-related Neurodevelopmental Disorder

Targeting Heterozygous Dominant Negative Variant of KCNA2 Using Gapmer ASO for the Treatment of Drug-Resistant Epilepsy